Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.

Aged; Antigens, CD/blood; Antigens, CD4/blood; Antigens, CD8/blood; Antigens, Differentiation, B-Lymphocyte/blood; Discriminant Analysis; Female; Humans; Immunoglobulin E/blood; Leukemia, Lymphocytic, Chronic, B-Cell/blood/immunology; Leukocyte Count; Lymphocytes; Male; Middle Aged; Receptors, Cell Surface/metabolism; Receptors, IgE/metabolism; Receptors, Interleukin-2/metabolism; Receptors, Transferrin/metabolism; Solubility

Abstract :

[en] We measured the soluble (s) receptors CD23, CD8, CD4, interleukin-2 receptor (IL-2R, CD25), and transferrin receptor (TfR, CD71), in normal serum and in patients with chronic lymphocytic leukemia (CLL) and evaluated them in relation to clinical and biological parameters of the disease, as well as serum immunoglobulin E (IgE). Compared to 31 normal individuals, 42 CLL patients had increased levels of sCD23 (98.4 +/- 127.7 versus 0.9 +/- 0.3 U/ml, p < 0.001), sIL-2R (6080 +/- 7030 versus 1420 +/- 640 pg/ml, p < 0.001), sTfR (12,100 +/- 11,250 versus 5000 +/- 1050 ng/ml, p < 0.001), and sCD8 (510 +/- 191 versus 234 +/- 89 U/ml, p < 0.001), but normal sCD4 levels. Mean sCD23 levels remained normal in patients with non-Hodgkin's lymphoma (other than small lymphocytic), Hodgkin's disease, hairy cell leukemia, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), multiple myeloma, or solid tumors. Advancing Rai clinical stage was associated with a progressive elevation of sCD23 (p < 0.001), while sCD8 (p < 0.05), sIL-2R (p < 0.001), and sTfR (p < 0.005) were highest in stage 2 patients. Discriminant analysis confirmed the value of soluble receptor determinations in the clinical evaluation of CLL patients. sCD23 correlated with sIL-2R (p < 0.001) and sTfR (p < 0.05) but not with sCD4 or sCD8, and displayed an inverse relationship with serum IgE (NS) and total gamma-globulin (p < 0.05). sIL-2R correlated with sCD23 (p < 0.001), sTfR (p < 0.001), sCD4 (p < 0.01), and sCD8 (p < 0.01). The lymphocyte count correlated with serum lactate dehydrogenase (LDH) (p < 0.05), sCD23 (p < 0.001) and sIL-2R (p < 0.01) but not sTfR, sCD8, or sCD4. Chemotherapy produced consistent reductions of sCD23 levels in two responding patients. We conclude that: (i) sCD23 is considerably elevated in CLL, correlates with the tumor mass and clinical stage, and could be helpful in monitoring these patients; and (ii) sIL-2R, sCD8, and sTfR levels are less specifically increased and could be influenced by other factors such as immune activation and erythropoiesis.

Disciplines :

Rheumatology
Hematology

Author, co-author :

Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Lampertz, S.

De Groote, D.

Igot, D.

Malaise, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie

Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

English

Title :

Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.

Publication date :

1993

Journal title :

Leukemia

ISSN :

0887-6924

eISSN :

1476-5551

Publisher :

Nature Publishing Group, London, United Kingdom

Volume :

Issue :

Pages :

2019-2025

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 16 February 2009

Statistics

Number of views

208 (4 by ULiège)

Number of downloads

12 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Freedman AS. Immunobiology of chronic lymphocytic leukemia. Hematol Oncol Clin North Am 1990;4:405-429.
Kvaloy S, Langholm R, Kaalhus O, Michaelsen T, Funderud S, Foss Abrahamsen A, Godal T. Transferrin receptor and B-lymphoblast antigen - their relationship to DNA synthesis, histology and survival in B-cell lymphomas. Int J Cancer 1984;33:173-177.
Scott CS, Ramsden W, Limbert HJ, Master PS, Roberts BE. Membrane transferrin receptor (TfR) and nuclear proliferation-associated Ki-67 expression in hemopoietic malignancies. Leukemia 1988;2:438-442.
Baldini L, Cro L, Cortelezzi A, Calori R, Nobili L, Maiolo AT, Polli EE. Immunophenotypes in 'classical' B-cell chronic lymphocytic leukemia. Correlation with normal cellular counterpart and clinical findings. Cancer 1990;66:1738-1742.
Kay NE, Burton J, Wagner D, Nelson DL. The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukine-2 receptors. Blood 1988;72:447-450.
Fournier S, Tran ID, Suter U, Biron G, Delespesse G, Sarfati M. The in vivo expression of type B CD23 mRNA in B-chronic lymphocytic leukemic cells is associated with an abnormally low CD23 upregulation by IL-4: comparison with their normal cellular counterparts. Leuk Res 1991;15:609-618.
Sarfati M, Fournier S, Christoffersen M, Biron G. Expression of CD23 antigen and its regulation by IL-4 in chronic lymphocytic leukemia. Leuk Res 1990;14:47-55.
Geisler CH, Larsen JK, Hansen NE, Hansen MM, Christensen BE, Lund B, Nielsen H, Plesner T, Thorling K, Andersen E. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991;78:1795-1802.
Norment AM, Lonberg N, Lacy E, Littman DR. Alternatively spliced mRNA encodes a secreted form of human CD8a. Characterization of the human CD8a gene. J Immunol 1989;142:3312-3319.
Mosley B, Beckmann MP, March CJ, Idzerda RL, Gimpel SD, Vandenbos T, Friend D, Alpert A, Anderson D, Jackson J, Wignall JM, Smith C, Gallis B, Sims JE, Urdal D, Widmer MB, Cosman D, Park LS. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell 1989;59:335-348.
Chitambar CR, Zivkovic Z. Release of soluble transferrin receptor from the surface of human leukemic HL60 cells. Blood 1989;74:602-608.
Shih YJ, Baynes RD, Hudson BG, Flowers CH, Skikne BS, Cook JD. Serum transferrin receptor is a truncated form of tissue receptor. J Biol Chem 1990;265:19077-19081.
Nakajima T, Sarfati M, Delespesse G. Relationship between human IgE-binding factors (IgE-BF) and lymphocyte receptors for IgE. J Immunol 1987;139:848-854.
Robb RJ, Kutny RM. Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol 1987;139:855-862.
Huizinga TWG, van der School CE, Jost C, Klaassen R, Kleijer M, Von dem Borne AEGK, Roos D, Tetteroo PAT. The PI-linked receptor FcRIII is released on stimulation of neutrophils. Nature 1988;333:667-669.
Beguin Y, Huebers HA, Josephson B, Finch CA. Transferrin receptors in rat plasma. Proc Natl Acad Sci USA 1988;85:637-640.
Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA. Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 1990;75:102-107.
Klemow D, Einsphar D, Brown TA, Flowers CH, Skikne BS. Serum transferrin receptor measurements in hematologic malignancies. Am J Hematol 1990;34:193-198.
Griffin DE, Ward BJ, Jauregui E, Johnson RT, Vaisberg A. Immune activation in measles. N Engl J Med 1989;320:1667-1672.
Griffin DE, McArthur JC, Cornblath DR. Soluble interleukin-2 receptor and soluble CD8 in serum and cerebrospinal fluid during human immunodeficiency virus-associated neurologic disease. J Neuroimmunol 1990;28:97-109.
Sawada S, Sugai S, Iijima S, Takei M, Paredes E, Hayama T, Nishinarita S, Hosokawa Y, Horie T, Obara T. Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjogren's syndrome. Am J Med 1992;92:134-140.
Symons JA, McCulloch JF, Wood NC, Duff GW. Soluble CD4 in patients with rheumatoid arthritis and osteoarthritis. Clin Immunol Immunopathol 1991;60:72-82.
Vibe Petersen J, Tvede N, Diamant M, Kjerulff AA, Sorensen HR, Andersen V. Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with non-resectable lung cancer. Cancer Immunol Immunother 1991;33:121-127.
Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 1990;113:619-627.
Pui CH, Ip SH, Thompson E, Dodge RK, Brown M, Wilimas J, Carrabis S, Kung P, Berard CW, Crist WM. Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcome. Blood 1989;73:209-213.
Pizzolo G, Chilosi M, Vinante F, Dazzi F, Lestani M, Perona G, Benedetti F, Todeschini G, Vincenzi C, Trentin L. Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer 1987;55:427-428.
Pui C-H, Ip SH, Dodge RK, Carrabis S, Brown M, Crist WM, Berard CW, Kung P, Dahl GV, Murphy SB. Serum levels of CD8 antigen in childhood lymphoid malignancies: a possible indicator of increased suppressor cell activity in poor-risk patients. Blood 1988;72:1015-1021.
Pui CH, Ip SH, Kung P, Dodge RK, Berard CW, Crist WM, Murphy SB. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood 1987;70: 624-628.
Pui CH, Ip SH, Iflah S, Behm FG, Grose BH, Dodge RK, Crist WM, Furman WL, Murphy SB, Rivera GK. Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia. Blood 1988;71:1135-1137.
Marcon L, Rubin LA, Kurman CC, Fritz ME, Longo DL, Uchiyama T, Edwards BK, Nelson DL. Elevated serum levels of soluble Tac peptide in adult T-cell leukemia: correlation with clinical status during chemotherapy. Ann Intern Med 1988;109:274-279.
Lal RB, Rudolph DL, Roberts C, Honda M. Elevated levels of soluble CD8 and soluble CD25 in patients with human T cell leukemia virus type I-associated myelopathy and adult T cell leukemia. J Infect Dis 1991;164:429-430.
Ho AD, Grossmann M, Knauf W, Martin H, Trumper L, Zwingers T, Sonnen R, Pralle H, Hunstein W. Plasma levels of soluble CD8 antigen and interleukin-2 receptor antigen in patients with hairy cell leukemia, relationship with splenectomy and with clinical response to therapy. Leukemia 1989;3:718-723.
Chilosi M, Semenzato G, Cetto G, Ambrosetti A, Fiore Donati L, Perona G, Berton G, Lestani M, Scarpa A, Agostini C, Trentin L, Zambello R, Masciarelli M, Dazzi F, Vinante F, Caligaris-Cappio F, Pizzolo G. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987;70:1530-1535.
Richards JM, Mick R, Latta JM, Daly K, Ratain MJ, Vardiman JW, Golomb HM. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood 1990;76:1941-1945.
Semenzato G, Foa R, Agostini C, Zambello R, Trentin L, Vinante F, Benedetti F, Chilosi M, Pizzolo G. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood 1987;70:396-400.
Musolino C, Di Cesare E, Alonci A, Allegra A, Orlando A, Grosso P, Squadrito G. Serum levels of CD8 antigen and soluble interleukin 2 receptors in patients with B cell chronic lymphocytic leukemia. Acta Haematol 1991;85: 57-61.
Semenzato G, Siviero F, Vinante F, Zambello R, Trentin L, Agostini C, Adami F, Vincenzi C, Zanotti R, Zuppini B. Serum levels of soluble CD8 are increased in patients with B chronic lymphocytic leukemia. Eur J Cancer Clin Oncol 1989;25:1577-1581.
Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, Ennis FA. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest 1991;88:1473-1480.
Yanagihara Y, Sarfati M, Marsh D, Nutman T, Delespesse G. Serum levels of IgE-binding factor (soluble CD23) in diseases associated with elevated IgE. Clin Exp Allergy 1990;20:395-401.
Dugas B, Mencia Huerta JM, Braquet P. The low affinity receptor for IgE (CD23) in human: a multifunctional receptor/cytokine? Eur Cytokine Netw 1992;3:35-41.
Suemura M, Kikutani H, Sugiyama K, Uchibayashi N, Aitani M, Kuritani T, Barsumian EL, Yamatodani A, Kishimoto T. Significance of soluble Fc epsilon receptor II (sFc epsilon RII/CD23) in serum and possible application of sFc epsilon RII for the prevention of allergic reactions. Allergy Proc 1991;12:133-137.
Hamada A, Watanabe N, Yanagihara Y, Barbosa I, Tateno S, Kobayashi A. Soluble CD23 in the serum of children with ascariasis. Trans R Soc Trop Med Hyg 1991;85:529-530.
Jyonouchi H, Voss RM, Krishna S, Urval K, Sjahli H, Welty PB, Good RA. Soluble Fc epsilon RII levels in normal children and patients with immunodeficiency diseases. J Allergy Clin Immunol 1991;87:965-970.
Sarfati M, Bron D, Lagneaux L, Fonteyn C, Frost H, Delespesse G. Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood 1988;71:94-98.
Lowe J, Brown B, Hardie D, Richardson P, Ling N. Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia. Immunol Lett 1989;20:103-109.
Gordon J, Cairns JA, Flores Romo L, Millsum MJ, Guy GR. Significance of soluble CD23 ('IgE-binding factor') in pathologic sera. Blood 1988;72:367-369.
Fridman WH, Mathiot C, Montcuit J, Teillaud JL. Fc receptors, immunoglobulin-binding factors and B chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988;30: 311-315.
Ling NR, Stevenson FK, Brown B. Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL). Clin Exp Immunol 1991;86:360-366.
Genot E, Sarfati M, Sigaux F, Petit Koskas E, Billard C, Mathiot C, Falcoff E, Delespesse G, Kolb JP. Effect of interferon-alpha on the expression and release of the CD23 molecule in hairy cell leukemia. Blood 1989;74: 2455-2463.
Rai KR, Sawitski A, Cronkite EP, Chanana AD, Levy RN, Pasternak BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
Beguin Y, Clemons G, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993;81:1067-1076.
Yokota A, Kikutani H, Tanaka T, Sato R, Barsumian EL, Suemura M, Kishimoto T. Two species of human Fc epsilon receptor II (Fc epsilon RII/CD23): tissue-specific and IL-4-specific regulation of gene expression. Cell 1988;55:611-618.
Foumier S, Delespesse G, Rubio M, Biron G, Sarfati M. CD23 antigen regulation and signaling in chronic lymphocytic leukemia. J Clin Invest 1992;89:1312-1321.
Ishida H, Kumagai S, Iwai K, Takahashi T, Kawabe T, Yodoi J, Aral N, Naniiuchi S, Konaka Y, Imura H. Heterogeneity in terms of interleukin 4-dependent regulation of Fc epsilonreceptor-CD23 expression on chronic B-lymphocytic leukemia cells. Immunol Lett 1989;20:323-330.
Carlsson M, Sundstrom C, Bengtsson M, Totterman TH, Rosen A, Nilsson K. Interleukin 4 strongly augments or inhibits DNA synthesis and differentiation of B-type chronic lymphocytic leukemia cells depending on the co-stimulatory activation and progression signals. Eur J Immunol 1989;19:913-921.
Delespesse G, Suter U, Mossalayi D, Battler B, Sarfati M, Hofstetter H, Kilcherr E, Debre P, Dalloul A. Expression, structure, and function of the CD23 antigen. Adv Immunol 1991;49:149-191.